RxDoctor Payments Data

Ruiz Haider, MD

Family Medicine · Mansfield, TXNPI 1871549006

Payments from drug & device makers

$2,046in general payments, 2019–2025

Across 140 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$1K
  • Sumitomo Pharma America, Inc.$100
  • Otsuka America Pharmaceutical, Inc.$97
  • AstraZeneca$88
  • Astellas Pharma US Inc$65
  • Pfizer$43
  • plus $253 from 10 others

What the payments were for

  • Food & beverage$1,96696%
  • Education$804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,046 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$120,861
Medicare patients
268
Services billed
1,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban666$213,330
BiktarvyBictegrav/Emtricit/Tenofov Ala20$83,174
JanuviaSitagliptin Phosphate64$50,234
JardianceEmpagliflozin125$48,779
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$42,197
NuedextaDextromethorphan Hbr/Quinidine47$39,860
XifaxanRifaximin21$33,901
XareltoRivaroxaban99$30,820
FarxigaDapagliflozin Propanediol31$26,400
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$21,622
MounjaroTirzepatide11$20,380
MyrbetriqMirabegron75$19,019
BrilintaTicagrelor72$16,237
LinzessLinaclotide17$15,322
GemtesaVibegron58$13,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$213,330666 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$88$64,260129 claims
Boehringer IngelheimJardiance$13$48,779125 claims
Johnson & JohnsonXarelto$32$30,82099 claims
Lilly USA, LLCMounjaro$30$20,38011 claims
Astellas Pharma US IncMyrbetriq$65$19,01975 claims
Sumitomo Pharma America, Inc.Gemtesa$100$13,99458 claims
Novo NordiskOzempic$18$13,67012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →